Aktiesnakken — Juni 2012
-
kender I det. Hvergang jeg læser relaps og refractory så giver det altså et gib i mig
-
modulation of enzymatic activation - hvorfor er det jeg skal forstå hvad det er?
-
jeg hader klinisk data i fase 1/2 i relaps og refractory patienter
-
jeg tror data er gode
-
har de sagt de skuffede?
-
det gode ved kliniske kræft data er at de altid kan en til at føle sig rimelig uvidende
-
der er respons i 18 ud af 29. Og de vil escalerer dosen. Ingen er døde med ordene "gid jeg havde fået rituxian"
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind